Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments utilizing Dynamic Pressure Sensing™ (DPS) technology, today highlighted the continued growth in clinical adoption and physician acceptance of its CompuFlo® Epidural System following the publication of new peer-reviewed research from the University of Texas Medical Branch (UTMB).

The newly published study in Operative Neurosurgery demonstrated that CompuFlo-guided epidural access during spinal cord stimulator (SCS) implantation procedures was associated with significantly lower complication rates compared with conventional loss-of-resistance techniques.

The publication further demonstrates the expanding clinical acceptance of CompuFlo technology across a broad and growing range of procedures requiring accurate epidural space identification, including:

  • Epidural Steroid Injections (ESIs)
  • Spinal Cord Stimulator (SCS) implantation
  • Chronic pain management procedures
  • Obstetric epidurals
  • Thoracic and cervical epidurals
  • Neuromodulation therapies
  • Surgical epidural anesthesia

CompuFlo provides physicians with continuous real-time pressure sensing and audible feedback during needle advancement, enabling objective identification of the epidural space and helping improve procedural precision, safety, and physician confidence.

In the UTMB study, CompuFlo guidance was associated with a 91% reduction in the odds of composite complications, including cerebrospinal fluid (CSF) leak, epidural blood patch, and postoperative radiculopathy in SCS procedures. The publication also references prior studies supporting CompuFlo use in obstetric epidurals, pain management procedures, thoracic epidurals, and surgical epidural applications, including reports of high procedural success rates and reduced accidental dural punctures.